www.westernjournal.com
Overnight: Moderna Stock Price Took a Steep Drop After FDA Rejected MRNA-Based Flu Shot Late Tuesday
Moderna stock tumbled 10.5 percent in pre-market trading early Wednesday morning, after the Food and Drug Administration rejected the drug giant's application for an experimental flu vaccine using mRNA technology. Currently, only COVID-19 vaccines use mRNA (messenger Ribonucleic Acid) technology. Health and Human Services director Robert F. Kennedy Jr. has...
New Posts (Home)
ChatBox
Popular Posts 
Game Zone
Top PodCasts
